Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NGOs Praise C-TAP COVID-19 Deals But Say Much More Needs To Be Done

The WHO Is Negotiating Additional Agreements

Executive Summary

With efforts continuing to maximize access to medical countermeasures against the pandemic threat, a webinar organized by NGOs looked at progress with and the shortcomings of the WHO’s C-TAP initiative, recent moves by the WHO on access provisions in funding agreements, and plans for a global C-TAP database.

You may also be interested in...



US To Share Its COVID-19 Technologies With World, Biden Says

During the second global COVID-19 summit, US President Joe Biden pledged to share essential technologies across the globe to fight the pandemic.

New UK Investment Facility To Boost Horizon-Scanning For Pipeline Drugs

An updated UK PharmaScan platform is to be delivered within the first three years of the new voluntary drug pricing scheme, with companies agreeing to provide “timely, accurate and comprehensive information” for all their medicines in development.

Voluntary Vs Statutory: Pharma Firms Soon To Choose Between Two UK Pricing Schemes

The UK’s new voluntary drug pricing and access deal is a “paradigm shift” that will see companies paying different levels of rebates depending on their product mix, with higher payments on older medicines making headroom for growth in newer drugs, according to one lawyer.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel